SK Bioscience Co Ltd
KRX:302440

Watchlist Manager
SK Bioscience Co Ltd Logo
SK Bioscience Co Ltd
KRX:302440
Watchlist
Price: 59 500 KRW -1% Market Closed
Updated: May 19, 2024
Section:
 

Relative Value

The Relative Value of one SK Bioscience Co Ltd stock under the Base Case scenario is hidden KRW. Compared to the current market price of 59 500 KRW, SK Bioscience Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SK Bioscience Co Ltd Relative Value
HIDDEN
Unlock
Worst Case
Base Case
Best Case

Valuation Multiples

12.4
P/S
P/S
Price to Sales
12.4
vs History
57
vs Industry
42
Median 3Y
13
Median 5Y
13
Industry
8.2
Forward
19.8
More Details
204.8
P/E
P/E
Price to Earnings
204.8
vs History
17
vs Industry
0
Median 3Y
95.1
Median 5Y
91.8
Industry
26.1
Forward
-87.5
More Details
155.8
P/OCF
P/OCF
Price to OCF
155.8
vs History
17
vs Industry
1
Median 3Y
42.5
Median 5Y
42.1
Industry
24.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
27.1
Median 5Y
25.6
Industry
23.4
More Details
2.7
P/B
P/B
Price to Book Value
2.7
vs History
90
vs Industry
36
Median 3Y
3.6
Median 5Y
3.6
Industry
2.6
More Details
9
EV/S
EV/S
Enterprise Value to Sales
9
vs History
72
vs Industry
40
Median 3Y
10.3
Median 5Y
10.1
Industry
7.4
Forward
14.3
More Details
23.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
23.3
vs History
50
vs Industry
23
Median 3Y
24.3
Median 5Y
24
Industry
9.1
More Details
145.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
145.5
vs History
9
vs Industry
0
Median 3Y
45.7
Median 5Y
45
Industry
4.6
Forward
-134.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
0
Median 3Y
23.3
Median 5Y
23.2
Industry
4.4
Forward
-48.7
More Details
113
EV/OCF
EV/OCF
Enterprise Value to OCF
113
vs History
17
vs Industry
1
Median 3Y
37.3
Median 5Y
37.1
Industry
6.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
22.4
Median 5Y
20.9
Industry
3.8
More Details
5.7
EV/IC
EV/IC
Enterprise Value to IC
5.7
vs History
87
vs Industry
31
Median 3Y
7.8
Median 5Y
7.7
Industry
4.9
More Details

Multiples Across Competitors

Competitors Multiples
SK Bioscience Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
SK Bioscience Co Ltd
KRX:302440
4.6T KRW 12.4 204.8 145.5 -276.5
US
Abbvie Inc
NYSE:ABBV
293.9B USD 5.4 49.4 13.8 21.3
US
Amgen Inc
NASDAQ:AMGN
167.6B USD 5.7 44.5 18.7 30.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115B USD 11.3 28.6 24 25.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
108.2B USD 8.3 28.1 22.7 25.2
AU
CSL Ltd
ASX:CSL
135.3B AUD 6.4 36.6 22.1 27.4
US
Gilead Sciences Inc
NASDAQ:GILD
84.4B USD 3.1 174.3 8.8 11.6
US
Moderna Inc
NASDAQ:MRNA
50.9B USD 9.9 -8.5 -9.4 -8.4
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
33.6B USD 3.5 28.8 14.6 18.3
KR
Celltrion Inc
KRX:068270
39.7T KRW 18.2 74.1 45.3 62.4
EV/EBIT Multiple
EBIT Growth
KR
SK Bioscience Co Ltd
KRX:302440
Average EV/EBIT: 27.8
Negative Multiple: -276.5 		N/A
US
Abbvie Inc
NYSE:ABBV
21.3
88%
US
Amgen Inc
NASDAQ:AMGN
30.9
95%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.1
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.2
51%
AU
CSL Ltd
ASX:CSL
27.4
69%
US
Gilead Sciences Inc
NASDAQ:GILD
11.6
33%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -8.4 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -55.8 N/A
US
Biogen Inc
NASDAQ:BIIB
18.3
71%
KR
Celltrion Inc
KRX:068270
62.4
188%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.